Literature DB >> 10656693

c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300.

A Tomita1, M Towatari, S Tsuzuki, F Hayakawa, H Kosugi, K Tamai, T Miyazaki, T Kinoshita, H Saito.   

Abstract

Transcription factor c-Myb plays important roles in cell survival and differentiation in immature hematopoietic cells. Here we demonstrate that c-Myb is acetylated at the carboxyl-terminal conserved domain by histone acetyltransferase p300 both in vitro and in vivo. The acetylation sites in vivo have been located at the lysine residues of the conserved domain (K471, K480, K485) by the use of the mutant Myb (Myb-KAmut), in which all three lysine residues are substituted into alanine. Electrophoretic mobility shift assay reveals that Myb-KAmut shows higher DNA binding activity than wild type c-Myb and that acetylation of c-Myb in vitro by p300 causes dramatic increase in DNA binding activity. Accordingly, transactivation activity of both mim-1 and CD34 promoters by Myb-KAmut is higher than that driven by wild type c-Myb. Furthermore, the bromodomain of p300, in addition to the histone acetyltransferase (HAT) domain, is required for effective acetylation of c-Myb, and hGCN5 is revealed to be a factor acetyl-transferase for c-Myb in vitro. We present a new manner of post-translational modification of the c-Myb protein and the potential significance of the acetylation in c-Myb.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656693     DOI: 10.1038/sj.onc.1203329

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  Interaction between acetylated MyoD and the bromodomain of CBP and/or p300.

Authors:  A Polesskaya; I Naguibneva; A Duquet; E Bengal; P Robin; A Harel-Bellan
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 2.  Acetylation of histones and transcription-related factors.

Authors:  D E Sterner; S L Berger
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

Review 3.  Insight into the tumor suppressor function of CBP through the viral oncoprotein tax.

Authors:  K Van Orden; J K Nyborg
Journal:  Gene Expr       Date:  2000

Review 4.  Important roles of reversible acetylation in the function of hematopoietic transcription factors.

Authors:  Xiaofang Huo; Junwu Zhang
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

5.  Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation.

Authors:  Manuela Delvecchio; Jonathan Gaucher; Carmen Aguilar-Gurrieri; Esther Ortega; Daniel Panne
Journal:  Nat Struct Mol Biol       Date:  2013-08-11       Impact factor: 15.369

6.  Histone modifiers in cancer: friends or foes?

Authors:  Idan Cohen; Elżbieta Poręba; Kinga Kamieniarz; Robert Schneider
Journal:  Genes Cancer       Date:  2011-06

7.  Acetylation of lysine 564 adjacent to the C-terminal binding protein-binding motif in EVI1 is crucial for transcriptional activation of GATA2.

Authors:  Akiko Shimahara; Norio Yamakawa; Ichiro Nishikata; Kazuhiro Morishita
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

8.  Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer.

Authors:  Yina Gao; Jingshu Geng; Xuan Hong; Jiping Qi; Yang Teng; Yang Yang; Di Qu; Gongyan Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

9.  p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.

Authors:  Sumit Isharwal; Michael C Miller; Cameron Marlow; Danil V Makarov; Alan W Partin; Robert W Veltri
Journal:  Prostate       Date:  2008-07-01       Impact factor: 4.104

10.  Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).

Authors:  Alexander M Taylor; Alexandre Côté; Michael C Hewitt; Richard Pastor; Yves Leblanc; Christopher G Nasveschuk; F Anthony Romero; Terry D Crawford; Nico Cantone; Hariharan Jayaram; Jeremy Setser; Jeremy Murray; Maureen H Beresini; Gladys de Leon Boenig; Zhongguo Chen; Andrew R Conery; Richard T Cummings; Leslie A Dakin; E Megan Flynn; Oscar W Huang; Susan Kaufman; Patricia J Keller; James R Kiefer; Tommy Lai; Yingjie Li; Jiangpeng Liao; Wenfeng Liu; Henry Lu; Eneida Pardo; Vickie Tsui; Jian Wang; Yongyun Wang; Zhaowu Xu; Fen Yan; Dong Yu; Laura Zawadzke; Xiaoqin Zhu; Xiaoyu Zhu; Robert J Sims; Andrea G Cochran; Steve Bellon; James E Audia; Steven Magnuson; Brian K Albrecht
Journal:  ACS Med Chem Lett       Date:  2016-03-15       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.